

# Silo Pharma Inc

12:00 22 Feb 2021

## Three companies pushing the field of psychedelic medicine forward to present at Proactive virtual conference on February 23

Aion Therapeutic Inc (CSE:AION), Silo Pharma Inc (OTCMKTS:SILO) and Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS:GTSIF) will be presenting at Proactive's next virtual showcase event on February 23.

The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1.00pm ET.

### SIGN-UP: Proactive One2One February 23

#### Silo Pharma: bridging the gap

#### Silo Pharma is bridging the gap between traditional pharmaceuticals and the emerging psychedelics space.

The developmental-stage biopharmaceutical company's mission is to identify assets to license and fund the research which it believes could transform both the well-being of patients and the healthcare system at large.

"In these uncertain times, the mental health of the nation and beyond is being put to the test. More than ever, creative new therapies and lines of thought are needed to address health challenges of today," Silo has said "Combining our resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space."

The company's management and founders have played key roles in numerous successful biotech companies. CEO Eric Weisblum will share the company's story and strategies for success at Tuesday's event.

[CLICK HERE TO REGISTER](#)

#### Lobe Sciences: advancing transformational treatments for brain injuries

Lobe Sciences is mastering the development of transformational medicines and devices as it builds a growing portfolio of intellectual property to support wellness and improve mental health.

The Vancouver-based company is currently advancing unique medicines and devices to treat mild traumatic brain injury and post-traumatic stress disorder, as well as other indications. With five provisional patents, a pre-clinical study underway and a drug delivery device in engineering development, Lobe is quickly making a name for itself in the world of psychedelics.


In December, Lobe sold its cannabis asset Cowlitz County Cannabis Cultivation to Ionic Brands, netting \$23 million and a stake in the latter company to keep a foothold in the red-hot US cannabis space.

CEO Phil Young will share the company's plans for the proceeds and Lobe's other strategic initiatives for 2021 with

**Price:** 0.285

**Market Cap:** \$24.28 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** SILO

**Listing:** OTCQB

**52 week**

High	Low
0.59	0.16

**Sector:** Pharma & Biotech

**Website:** [silopharma.com](http://silopharma.com)

#### Company Synopsis:

*Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Silo Pharma Inc's mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. In these uncertain times, the mental health of the nation and beyond is being put to the test.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

event participants on Tuesday.

[CLICK HERE TO REGISTER](#)

### **Aion Therapeutic: using artificial intelligence to create a full lineup of psychedelic and cannabis therapies**

Toronto-based Aion Therapeutic Inc (CSE:AION) recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic mushrooms.

The applications include formulations designed to treat a variety of conditions, including cancer, psychiatric disorders, addiction, viral diseases, obesity and inflammatory disorders.

Aion's combinatorial treatment formulation discovery platform relies on artificial intelligence (AI) techniques. By utilizing AI, the company plans to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals, as well as individualized treatments for personalized medicine using human genome and other data.

Executive chairman Dr Stephen Barnhill will take participants through the firm's pharmaceutical research and product development. Aion also operations in Jamaica, where psychedelics are more available.

[CLICK HERE TO REGISTER](#)

About the event:

- Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
- We look beyond the numbers and meet the people creating the value for shareholders

The format:

- Each company has a presentation slot followed by Q&A, giving you the chance to discover the real story
- You can watch the event afterwards on our YouTube channel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Silo Pharma Inc named herein, including the promotion by the Company of Silo Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).